Core Viewpoint - Baiyunshan (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has registered the Phase II clinical trial information for its pediatric Xiaochaihu granules on the National Medical Products Administration's clinical trial registration and information disclosure platform [1] Group 1 - The clinical trial is designed to evaluate the efficacy and safety of pediatric Xiaochaihu granules in treating pediatric gastrointestinal colds with Shaoyang syndrome through a randomized, double-blind, parallel-controlled, multi-center Phase II clinical study [1] - The common title of the trial is "Phase II Clinical Trial of Pediatric Xiaochaihu Granules for Treating Pediatric Gastrointestinal Colds with Shaoyang Syndrome" [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has registered the Phase II clinical trial information for its pediatric Xiao Chai Hu granules on the National Medical Products Administration's clinical trial registration and information disclosure platform [1] Group 1 - The clinical trial is designed to evaluate the efficacy and safety of pediatric Xiao Chai Hu granules in treating pediatric gastrointestinal colds with Shaoyang syndrome through a randomized, double-blind, parallel-controlled, multi-center Phase II clinical study [1] - The common title of the trial is "Phase II Clinical Trial of Pediatric Xiao Chai Hu Granules for Treating Pediatric Gastrointestinal Colds with Shaoyang Syndrome" [1]

试验专业题目：儿童小柴胡颗粒治疗小儿胃肠型感冒邪犯少阳证有效 性及安全性的随机、双盲、平行对照设计、多中心Ⅱ期临床研究 证券代码：600332 证券简称：白云山 公告编号：2025－072 广州白云山医药集团股份有限公司 关于子公司药物进入 II 期临床试验的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（"公司"）子公司广州白云山光 华制药股份有限公司（"光华药业"）研发的儿童小柴胡颗粒于近日在国 家药品监督管理局药物临床试验登记与信息公示平台公示了II期临床试 验登记信息，现将相关情况公告如下： 一、临床试验相关情况 药物名称：儿童小柴胡颗粒 申请人名称：广州白云山光华制药股份有限公司 试验登记号：CTR20253842 试验方案编号：GZBYS-ETXCHKL-Ⅱ 试验通俗题目：儿童小柴胡颗粒治疗小儿胃肠型感冒邪犯少阳证Ⅱ期 临床试验 二、药物其他相关情况 儿童小柴胡颗粒主要用于小儿胃肠型感冒（邪犯少阳证）。 光华药业于2023年5月获得国家药品监督管理局签发的《药物临床试 1 验批 ...

Core Viewpoint - Baiyunshan (600332) announced that its subsidiary Guanghua Pharmaceutical has recently registered the Phase II clinical trial information for its children's Xiao Chai Hu granules on the National Medical Products Administration's clinical trial registration and information disclosure platform [1] Group 1 - The announcement was made on September 22 [1] - The product in focus is children's Xiao Chai Hu granules, which is a traditional Chinese medicine [1] - The registration of the clinical trial indicates progress in the development of this pediatric medication [1]

白云山公告，子公司广州白云山光华制药股份有限公司研发的儿童小柴胡颗粒于近日在国家药品监督管 理局药物临床试验登记与信息公示平台公示了II期临床试验登记信息。该药物主要用于小儿胃肠型感冒 （邪犯少阳证），目前国内外尚无同类产品上市。截至公告日，该项目已投入研发费用约1858.79万元 （未经审计）。 ...

Core Viewpoint - Yatani Group (00789) experienced a significant stock price increase, rising over 48% during trading, with a current increase of 38.33% to HKD 0.142, and a trading volume of HKD 2.2969 million [1] Group 1: Strategic Partnership - Yatani Group announced a strategic cooperation agreement with Baiyunshan Weiyi, aimed at jointly developing products in the health and wellness sector and expanding market reach [1] - The collaboration will focus on innovative products in areas such as natural plant extracts, functional health products, and personal care items [1] - Both companies plan to promote the developed products and existing related products in overseas markets [1] Group 2: Business Development Strategy - The announcement aligns with Yatani Group's recent efforts to expand its sales business in beauty and health products [1] - The board believes that this strategic partnership will leverage Yatani Group's international market and sales platform advantages alongside Baiyunshan Weiyi's technical, brand, and product strengths, creating synergies [1] - This initiative is expected to enrich the company's product portfolio and enhance its core competitiveness in the health and wellness sector, opening new revenue streams [1]

Core Viewpoint - Yatani Group (00789) has seen a significant stock price increase of over 48% during trading, attributed to the announcement of a strategic cooperation agreement with Baiyunshan Weiyi to jointly develop products in the health sector [1] Group 1: Strategic Cooperation - The agreement aims to collaborate on the research and development of products in the health sector, including natural plant extracts, functional health products, and personal care items [1] - Both companies plan to market the developed products and existing related products in overseas markets [1] Group 2: Business Development Strategy - Yatani Group has been actively expanding its sales of beauty and health products in recent years, aligning with the strategic cooperation with Baiyunshan Weiyi [1] - The board believes that this partnership will leverage Yatani's international market and sales platform alongside Baiyunshan Weiyi's technology, brand, and product advantages, creating synergies [1] - This collaboration is expected to enrich Yatani's product portfolio and enhance its core competitiveness in the health sector, potentially opening new revenue streams [1]

Core Viewpoint - The event held in Yantai focused on the theme of "Inheriting Good Traditional Practices and Family Values," showcasing the integration of traditional Chinese medicine culture with modern public welfare initiatives [1][9]. Group 1: Company Initiatives - Baiyunshan Xiaochaihu, a member of the Fortune Global 500 company Guangyao Group, demonstrated its commitment to public welfare through various initiatives, including pandemic donations, rural revitalization, educational support, and cultural inheritance [9]. - The company presented "Good Family Values Commemorative Plaques" to partners during the event, symbolizing the ongoing transmission of these values [9]. Group 2: Cultural and Community Engagement - The event featured family stories from four local families, highlighting the importance of family values and their real-life applications, such as a driver saving a student in distress and stories of ethnic unity and dedication to medical ethics [4]. - Traditional cultural displays and modern artistic performances, including drum music and martial arts, showcased the hope of cultural inheritance and the fusion of traditional and modern elements [6]. Group 3: Audience Interaction - The event included interactive segments such as audience Q&A and games, encouraging participation and enhancing the understanding of traditional Chinese medicine and family values in a relaxed atmosphere [13].

Group 1 - The core point of the news is that Atnini Group has signed a strategic cooperation agreement with Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. to jointly develop products in the health sector and expand market reach, with a cooperation period of one year [1] - The strategic cooperation will focus on joint product development in areas such as natural plant extracts, functional health products, and personal care products [1] - Baiyunshan Weiyi will provide brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion related to health products [1] Group 2 - The cooperation aligns with Atnini Group's business development strategy and long-term layout in the health industry, aiming to leverage the advantages of both companies [2] - The board believes that this strategic cooperation will enhance the product portfolio and core competitiveness in the health sector, potentially opening new revenue sources [2] - The agreement is considered beneficial for the company and its shareholders overall [2]

Group 1 - The core point of the article is that Atnini Group has signed a strategic cooperation agreement with Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. to jointly develop products in the health sector and expand market reach, with a cooperation period of one year [1][2] - The strategic cooperation will focus on joint product development in areas such as natural plant extracts, functional health products, and personal care products [1] - Baiyunshan Weiyi will provide brand marketing support, including brand strategy, trademark licensing, and technical consulting for sales and market promotion related to health products [1] Group 2 - The cooperation aligns with Atnini Group's business development strategy and long-term layout in the health industry, aiming to leverage the strengths of both companies for synergistic effects [2] - This partnership is expected to enrich Atnini Group's product portfolio and enhance its core competitiveness in the health sector, potentially opening new revenue streams [2] - The board of directors believes that the agreement with Baiyunshan Weiyi is in the overall interest of the company and its shareholders [2]